Otsuka's Voyxact hits key secondary endpoint in Phase 3 IgA nephropathy trial as BioNTech cuts revenue outlook

Otsuka announced that its experimental kidney drug Voyxact met a key secondary endpoint in the Phase 3 VISIONARY study of patients with IgA nephropathy.

The positive result suggests the therapy had a beneficial impact on the disease marker assessed in the trial.

At the same time, BioNTech revised its revenue outlook downward, signaling a more cautious market expectation.